As our understanding of the intricate biology of CRPC deepens, encompassing AR signaling plasticity, tumor heterogeneity, epigenetic reprogramming, immune evasion mechanisms, and the dynamic interplay between tumor cells and the microenvironment, the development of more potent and targeted therapies becomes essential to improving treatment outcomes and enhancing the quality of life for CRPC patients [9,10]. This evidence concerns the gene AR and neoplasm.